NICE Clears Pradaxa For DVT, Setting Up Another Clash With Xarelto
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indication.